Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyoctamide SCHEMBL667731 | 1.00 | ADORA3 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Heptolamide SCHEMBL1814750 | 1.00 | ADORA3 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Glycyclamide SCHEMBL21722119 | 0.99 | ADORA3 (0.97) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Tolpentamide SCHEMBL2109411 | 0.98 | ADORA3 (0.97) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL5931113 | 0.87 | ADORA3 (0.77) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Acetohexamide SCHEMBL15669221 | 0.86 | ALDH1A1 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| Acetohexamide SCHEMBL37620 | 0.86 | ALDH1A1 (1.00) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL24162711 | 0.85 | PPARG (0.76) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL23007557 | 0.85 | ADORA3 (0.74) | ADORA3ALDH1A1TSHRLMNATHRB | |
| SCHEMBL23736042 | 0.85 | ADORA3 (0.74) | ADORA3ALDH1A1TSHRLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2038 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-12186329-B2 | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-07 | — | — | US | claimed |
| US-20240316048-A1 | Prevention of Pancreatic Cell Degeneration | MELIOR PHARMACEUTICALS I, INC. | 2024-09-26 | — | — | US | claimed |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | claimed |
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | claimed |
| CN-115799599-A | Preparation method of in-situ cured soft package battery and in-situ cured soft package battery | 上海空间电源研究所 | 2023-03-14 | — | — | CN | claimed |
| US-20220184070-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute for Global Health (AU) | 2022-06-16 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| US-6150383-A | COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-21 | — | — | US | claimed |
| CN-1264302-A | Treatment of diabetes with thiazolidinediones and sulfonylureas | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | CN | claimed |
| CN-1263467-A | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | SMITHKLINE BEECHAM PLC (GB) | 2000-08-16 | — | — | CN | claimed |
| WO-2000027401-A1 | COMBINATIONS FOR DIABETES WHICH CONTAIN A SULFONYLUREA, A GLITAZONE AND A BIGUANIDE | WARNER-LAMBERT COMPANY (US) | 2000-05-18 | — | — | WO | claimed |
| CN-1244801-A | Sulfonylurea-glitazone synergistic combinations for diabetes | WARNER LAMBERT CO (US) | 2000-02-16 | — | — | CN | claimed |
| US-6011049-A | Combinations for diabetes | WARNER-LAMBERT COMPANY (US) | 2000-01-04 | — | — | US | claimed |
| EP-0957923-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER-LAMBERT COMPANY (US) | 1999-11-24 | — | — | EP | claimed |
| US-5972973-A | SYNERGISTIC MIXTURE; GLUCOSE CONTROL | WARNER-LAMBERT COMPANY (US) | 1999-10-26 | — | — | US | claimed |
| US-5859037-A | MIXTURE SYNERGISTIC FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS IN HUMANS, WHICH ALSO IMPROVES GLYCEMIC CONTROL | WARNER-LAMBERT COMPANY (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998036755-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER LAMBERT COMPANY (US) | 1998-08-27 | — | — | WO | claimed |